Johnson & Johnson (JNJ) Earnings Date & Reports

Key Takeaways

• Johnson & Johnson reported third-quarter 2026 revenue of $25.40 billion, up 5.9% year over year and ahead of consensus estimates near $25.3 billion.
• Adjusted earnings per share (EPS) came in at $2.59, beating the $2.53 consensus, even as adjusted EPS declined 7.5% from the prior-year period.
• GAAP (Generally Accepted Accounting Principles) diluted EPS fell to $0.09, weighed down by roughly $7 billion in one-time charges tied to a proposed talc litigation resolution, the Firefly Bio acquisition, and a Sail Biomedicines collaboration.
• Innovative Medicine led the quarter with 7.7% reported sales growth, while the MedTech (medical technology) segment grew a more modest 2.5% operationally.
• Management raised full-year 2026 guidance for both sales and adjusted EPS, putting the company on track to surpass $100 billion in annual revenue for the first time in its history.

Earnings Context and Why It Matters

Johnson & Johnson's third-quarter results, reported on October 13, 2026, offer a window into whether the healthcare giant can sustain momentum as blockbuster drug Stelara faces generic competition and its medical device business navigates international headwinds. The quarter matters to investors because it tests the company's ability to offset a major patent-related revenue decline with newer oncology and immunology therapies, while also validating management's portfolio focus following the Kenvue consumer-health separation. With CEO Joaquin Duato positioning JNJ to become a leading oncology player and CFO Joseph Wolk guiding toward a historic $100 billion revenue year, this report is a key checkpoint on execution, cost discipline, and the durability of growth across both business segments.

Reported Results

Johnson & Johnson delivered third-quarter sales of $25.40 billion, a 5.9% increase from the prior-year quarter and slightly above the roughly $25.3 billion Wall Street had expected. Operational sales, which exclude currency translation effects, rose 6%. Adjusted earnings per share came in at $2.59, topping the $2.53 consensus by $0.06, though the figure marked a 7.5% year-over-year decline.

On a GAAP basis, diluted EPS was just $0.09, reflecting approximately $7 billion in charges related to the proposed talc litigation resolution, the acquisition of Firefly Bio, and the strategic collaboration with Sail Biomedicines. The Innovative Medicine segment generated $16.76 billion in sales, up 7.7% reported and 7.9% operationally, driven by oncology treatments such as Darzalex, Carvykti, Tecvayli, and Rybrevant/Lazcluze, alongside immunology drug Tremfya and neuroscience therapies Spravato and Caplyta. Those gains helped offset a 54% drop in Stelara sales. MedTech revenue reached $8.64 billion, up 2.5% operationally, with cardiovascular electrophysiology and Shockwave products contributing growth.

Management raised its full-year 2026 outlook, now projecting reported sales of $101.0 billion to $101.4 billion and adjusted EPS of $11.05 to $11.15, up from the prior range of $10.96 to $11.11.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening, making it a practical companion for monitoring earnings-driven moves and sector rotation. Explore the AI Screener to refine your own watchlists and uncover new opportunities.

Market Reaction and Investor Sentiment

Despite beating consensus estimates and raising guidance, Johnson & Johnson shares slipped following the report, falling roughly 4% at the open and trading down more than 5% intraday. The disconnect between the headline beat and the stock's decline highlights investors' focus on the quality and breadth of the quarter. Analysts noted that results were largely in line with, rather than clearly ahead of, elevated expectations, and that the market had grown accustomed to larger beats.

Investor sentiment was also tempered by the softer-than-expected MedTech performance, where operational growth of 2.5% fell short of what some had anticipated, and by weakness in cardiovascular and surgery businesses outside the U.S. Additionally, management's disclosure that the Firefly Bio and Sail Biomedicines transactions would pressure 2027 adjusted earnings by roughly $1.36 per share contributed to a more cautious near-term view, even as the company reaffirmed confidence in its longer-term growth trajectory.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will watch whether Johnson & Johnson can sustain its pharmaceutical momentum while addressing the slower-growth areas of its MedTech segment. Management has signaled confidence in a strong finish to 2026 and described 2027 as an even better year, but that optimism depends on several execution factors.

In Innovative Medicine, the key question is whether newer oncology and immunology products can continue to offset the ongoing erosion of Stelara and other legacy therapies. The company has outlined an ambition to become the world's leading oncology player by 2030, with oncology sales projected to exceed $50 billion, making pipeline catalysts and new drug approvals a critical area to monitor.

In MedTech, management is counting on new product launches, including the OTTAVA robotic surgery system and the VARIPULSE Pro electrophysiology catheter, to restore faster growth. Investors should also track the planned tax-free spinoff of the DePuy Synthes orthopedics business, targeted for mid-2027, which management views as a value-creating move.

Finally, watch for the earnings impact of the Firefly Bio and Sail Biomedicines transactions, which are expected to reduce full-year 2027 adjusted EPS by approximately $1.36 per share. Together with margin trends and cost discipline, these factors will shape how investors assess the sustainability of the company's growth narrative in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations